Kancera announces the outcome of the company’s rights issue

The board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...

Read More

Time plan for Kancera’s rights issue

Today, Friday, April 27, 2018 is the last day of trading in Kancera’s share, including the right to participate in the rights issue. Otherwise, the following time plan applies (dates refer to 2018):  Friday April 27th: Last day for trading...

Read More

Kancera Implements Rights Issue to Develop the Company´s ROR Technology

Kancera is announcing today that the company has raised SEK 7.6m before issue costs in a rights issue. The capital raised will be used to further develop the company's ROR technology to attack solid tumors.

Read More

Kancera’s new share issue oversubscribed

Kancera AB’s new share issue to the public ahead of listing on the NASDAQ OMX First North market was oversubscribed. The new share issue comprised 3,600,000 shares. The issue price was SEK 7 per share, which means that Kancera...

Read More